Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lactobacillus paracasei DTA81
- Development stage
- Preclinical
- Lead developer
- Universidade Federal de Viçosa
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Lactobacillus paracasei DTA81 is a probiotic bacterial strain investigated for its potential chemopreventive and therapeutic effects in colorectal cancer (CRC). In preclinical studies, DTA81 administration has been shown to reduce liver oxidative stress by lowering levels of malondialdehyde and carbonyl protein. It also modulates the colonic immune response, leading to decreased levels of pro-inflammatory cytokines such as Interleukin-6 (IL-6) and Interleukin-17 (IL-17). Additionally, the strain appears to inhibit cell proliferation in the colon, as indicated by reduced expression of proliferating cell nuclear antigen (PCNA). DTA81 also promotes a favorable gut microbiome composition, increasing the abundance of the genus Ruminiclostridium and elevating the production of short-chain fatty acids (SCFAs), particularly acetic acid, which are associated with improved intestinal health.
- Other names
- L. paracasei DTA81Lacticaseibacillus paracasei DTA81
02
Targets
IL-17A (Interleukin-17A)IL-6 (Interleukin 6)PCNA (Proliferating cell nuclear antigen)
Beyond the preview
Go deeper on Lactobacillus paracasei DTA81.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lactobacillus paracasei DTA81.